US updates guidelines on use of ARVs during pregnancy

HIV Treatment Bulletin - Vol. 8, No. 11&12, November/December 2007

The Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States have undergone a complete revision and reorganisation to reflect important new information, and to make them more user-friendly.

The guidelines have been restructured into principles for medical management of the woman and her infant during the antepartum, intrapartum, and postpartum period, including panel recommendations for each section.

Changes to the report include the following:

• Due to contamination with ethyl methane sulfonate (EMS), nelfinavir is no longer recommended for use in pregnant HIV-infected women
• New sections on antepartum management of HIV-infected pregnant women in special situations, including HBV and HCV coinfection
• New information on ARV drug choice and continuation during labor, and management of women not receiving antepartum ARVs
• New sections on choice and management of infant ARV prophylaxis
• Two new tables: “Results of Major Studies on ARV Prophylaxis to Prevent Mother-to-Child HIV Transmission” and “Clinical Scenario Summary Recommendations for ARV Use by Pregnant HIV-Infected Women and Prevention of Perinatal HIV-1Transmission in the U.S.”
• Updated information for emtricitabine, tenofovir, amprenavir, atazanavir, lopinavir/ritonavir, nelfinavir, maraviroc, and raltegravir in Table 2, “Preclinical & Clinical Data Relevant to the Use of ARVs in Pregnancy”
• Updated information for tenofovir, saquinavir-HGC, atazanavir, nelfinavir, maraviroc, and raltegravir in Table 3, “ARV Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy”

The updated guidelines are available in the “Guidelines” section of the AIDSinfo Web site under ‘Perinatal Guidelines’

You can download the guidelines or can request to receive them by e-mail or regular mail on the AIDSinfo website

2008-11-01
IB070811-14

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.